CAP TODAY/Daiichi-Sankyo/AstraZeneca Webinar: A Pathologist's View on a New Treatment Option for HER2 Expression in mBC

Thank you

This live web event has ended. Thank you for attending.

Description

A Pathologist’s View
on a New Treatment Option
for HER2 Expression in mBC

Why should you register now for this webinar?

HER2 has been, and continues to be, a practice-changing biomarker for guiding treatment decisions in breast cancer.
Recently, a new treatment option became available for certain patients with metastatic breast cancer (mBC), unlocking the need to take a fresh look at HER2 diagnostic approach.
In this session, Dr. David Hicks will provide you with details about this new indication, requirements for diagnostic testing, and a perspective on what this means for pathologists and the pathology laboratory.

Brought to you by CAP TODAY
Moderated by Bob McGonnagle, Publisher, CAP TODAY
Presenter: David Hicks, MD
You will have the opportunity to ask questions of our distinguished presenter

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc, and AstraZeneca. The speaker is being compensated for the presentation. This program is not CME accredited and may not be used for CME accreditation.
© 2022 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-8201a-1534 09/22

Contributors

David Hicks, MD

Professor and Director of IHC-ISH Laboratory and Breast Subspecialty Service
University of Rochester Medical Center
Bob McGonnagle

Publisher, CAP TODAY